Immune checkpoint inhibitors and cardiovascular toxicity.

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J
Lancet Oncol. 2018 19 (9): e447-e458

PMID: 30191849 · DOI:10.1016/S1470-2045(18)30457-1

Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-mediated immune responses against cancer cells. Immune checkpoint inhibitors have shown important benefits in phase 3 trials, and several agents have been approved for specific malignancies. Although adverse events from immune checkpoint inhibitors are a common occurrence, cardiotoxic effects are uncommon, but are often serious complications with a relatively high mortality. Most cardiotoxic effects appear to be inflammatory in nature. Clinical assessment of a combination of biomarkers, electrocardiography, cardiac imaging, and endomyocardial biopsy can be used to confirm a possible diagnosis. In this Review, we discuss the epidemiology of immune checkpoint inhibitor-mediated cardiotoxic effects, as well as their clinical presentation, subtypes, risk factors, pathophysiology, and clinical management, including the introduction of a new surveillance strategy.

Copyright © 2018 Elsevier Ltd. All rights reserved.

MeSH Terms (9)

Antineoplastic Agents, Immunological Cardiotoxicity Heart Heart Diseases Humans Neoplasms Risk Assessment Risk Factors Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: